Role of Nitric Oxide in the Antipruritic Effect of WIN 55,212-2, a Cannabinoid Agonist

Basit Öğe Kaydı
dc.authoridGunduz, Ozgur/0000-0002-2470-3021
dc.authoridGercek, Oyku Zeynep/0000-0002-3502-2977
dc.authorwosidGunduz, Ozgur/A-2351-2016
dc.authorwosidGÜNDÜZ, Özgür/AAH-8717-2019
dc.contributor.authorGercek, Oyku Zeynep
dc.contributor.authorOflaz, Busra
dc.contributor.authorOguz, Neslihan
dc.contributor.authorDemirci, Koray
dc.contributor.authorGunduz, Ozgur
dc.contributor.authorUlugol, Ahmet
dc.date.accessioned2024-06-12T10:55:36Z
dc.date.available2024-06-12T10:55:36Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: For centuries, cannabinoids are known to be effective in pain relief. Itch is an unpleasant sensation that provokes a desire to scratch. Since itch and pain are two sensations sharing a lot in common, we aimed to investigate whether the cannabinoid agonist WIN 55,212-2 reduces serotonin-induced scratching behavior and also observe whether modulation of Nitric Oxide (NO) production mediates the antipruritic effect of WIN 55,212-2. Methods: Scratching behavior is induced by intradermal injection of serotonin (50 mu g/50 mu L/mouse) to BALB/c mice. The cannabinoid agonist WIN 55,212-2 (1, 3, 10 mg/kg, IP) was given 30 min before serotonin injection. To observe the effect of NO modulation on the antipruritic effect of cannabinoids, the endothelial nitric oxide synthase (NOS) inhibitor L-NAME (3 mg/kg, IP), the neuronal NOS inhibitor 7-nitroindazole (3 mg/kg, IP), and the NO precursor L-arginine (100 mg/kg, IP) were administered together withWIN 55,212-2. Results: WIN 55,212-2 reduced serotonin-induced scratches at higher doses (3, 10 mg/kg; P<0.0001). The endothelial NOS inhibitor L-NAME, the neuronal NOS inhibitor 7-nitroindazole, and the nitric oxide precursor L-arginine did not influence the antipruritic action of WIN 55,212-2. When NO modulators were used alone, only the neuronal NOS inhibitor 7-nitroindazole attenuated serotonin-induced scratches (P<0.0001). Conclusion: Our findings indicate that exogenous cannabinoids may attenuate serotonin-induced scratches and NO does not mediate the antipruritic effect of WIN 55,212-2. On the other hand, neuronal NOS inhibition may play a role in the production of serotonin-induced scratches. Highlights Exogenous cannabinoids reduce serotonin-induced scratching behavior. Nitric oxide does not mediate the antipruritic action of cannabinoids. Cannabinoids have the potential to be used as antipruritic drugs. Plain Language Summary Cannabinoid drugs are not used effectively due to their potential drug abuse and side effects. For centuries, cannabinoids are known to exert analgesic actions, but they also produce antipruritic effects. There are numerous studies on the mechanisms of the analgesic effects of cannabinoids; however there are only a few research on their antipruritic mechanism of action. In this study, we observed the modulatory role of nitric oxide in the effect of cannabinoids on serotonininduced scratches which nitric oxide did not play role in this action. We induced scratching behavior by administering serotonin intradermally. Then we injected the cannabinoid agonist WIN 55,212-2 and observed the reduction of the scratching behavior. Afterwards, we administered an endothelial nitric oxide synthase inhibitor, a neuronal nitric oxide synthase inhibitor, and a nitric oxide precursor and showed that nitric oxide does not mediate the antipruritic effects of WIN 55,212-2. Whatever the mechanism of action, cannabinoids have the potential to be used as antipruritic drugs, especially if their side effects are reduced.en_US
dc.description.sponsorshipTrakya University Research Council [TUBAP-2015/198]en_US
dc.description.sponsorshipThis research was supported by Trakya University Research Council (TUBAP-2015/198).en_US
dc.identifier.doi10.32598/bcn.9.10.465
dc.identifier.endpage480en_US
dc.identifier.issn2008-126X
dc.identifier.issn2228-7442
dc.identifier.issue4en_US
dc.identifier.pmid33613885en_US
dc.identifier.scopus2-s2.0-85094952983en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage473en_US
dc.identifier.urihttps://doi.org/10.32598/bcn.9.10.465
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19486
dc.identifier.volume11en_US
dc.identifier.wosWOS:000585810200010en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherIran Univ Medical Sciencesen_US
dc.relation.ispartofBasic And Clinical Neuroscienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCannabinoid Systemen_US
dc.subjectNitric Oxideen_US
dc.subjectPruritusen_US
dc.subjectSerotoninen_US
dc.subjectWIN 55,212-2en_US
dc.subjectEndocannabinoid Modulationen_US
dc.subjectSynthase Inhibitionen_US
dc.subjectScratching Behavioren_US
dc.subjectTherapeutic Targeten_US
dc.subjectResponsesen_US
dc.subjectItchen_US
dc.subjectInvolvementen_US
dc.subjectPainen_US
dc.subjectReceptorsen_US
dc.subjectToleranceen_US
dc.titleRole of Nitric Oxide in the Antipruritic Effect of WIN 55,212-2, a Cannabinoid Agonisten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu